Life Sciences Tools and Services
Company Overview of GATC Biotech AG
GATC Biotech AG provides DNA and RNA sequencing, and bioinformatics solutions to academic and industrial customers. The company sequences various bacterial, plant, and other whole genomes, as well as whole human genomes. It provides Sanger sequencing services, including SUPREMErun, a sequencing service for plasmids or PCR fragments; and LIGHTrun, a Sanger sequencing service for purified plasmids or PCR fragments. The company also offers InView Human Exome, a solution that provides faster variant detection for clinical research and translational studies; InView 1-Week Exome Diagnostic; InView Human Kinome; InView De novo Genome 2.0, a solution that facilitates the generation and bioinformatic...
Founded in 1990
Key Executives for GATC Biotech AG
Co-Founder, Chief Executive Officer and Executive Director
Co-Founder, Chief Technology Officer and Executive Director
Chief Operating Officer and Executive Director
Director Strategic Marketing & Corporate Communication
Compensation as of Fiscal Year 2016.
GATC Biotech AG Key Developments
Qiagen NV Partners with GATC Biotech to Offer Clients Full Access to Ingenuity
Mar 19 15
QIAGEN N.V. announced a commercial agreement with GATC Biotech to provide GATC clients full access to QIAGEN's Ingenuity Variant Analysis solution for analysis and interpretation of genetic data. The access will take the form of interpretation services and direct access to Ingenuity Variant Analysis as a feature of the GATC Biotech's services. Ingenuity Variant Analysis is a powerful bioinformatics platform enabling laboratories to efficiently evaluate data generated by high-throughput next-generation sequencing (NGS) technologies. The QIAGEN software quickly filters genetic variants in a secure, private cloud-based environment to identify variants most likely to cause disease, drawing upon the Ingenuity Knowledge Base.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries